Choosing a Metabolic Disease Model
Four questions before the model
| Question | Why it decides the tier |
|---|---|
| Which tissue lost control? | Determines the cell type, and whether a monoculture suffices |
| What timescale is the phenotype? | Hours needs a cell system; months needs an animal or a cohort |
| Is a systemic component part of the mechanism? | If yes, no dish can model it |
| Does the outcome require architecture? | Fibrosis, gradients and barrier function need 3D or tissue |
A model chosen before these four are answered is usually chosen by convenience, and the resulting claim is usually narrower than the paper states.
The tiers
| Tier | Supports | Cannot support | Typical time |
|---|---|---|---|
| Immortalised line | Mechanism, screening, dose–response | Tissue identity, systemic effects, chronic set point | Days–weeks |
| Primary cell | Physiological metabolism, short-term regulation | Long-term adaptation; dedifferentiation within days | Days |
| iPSC-derived | Genotype-defined, patient-specific questions | Mature function; adult metabolic programmes | Weeks–months |
| Organoid | Architecture, cell–cell interaction, secretion | Vascular supply, immune cells, systemic hormones | Weeks–months |
| Spheroid | Gradients, penetration, 3D geometry | Stroma, vasculature, immune context | Days–weeks |
| Mouse | Integrated physiology, chronic set point | Human-specific biology; cost and throughput | Months |
| Human cohort | The disease itself, associations | Causation; mechanism | Years |
Important distinction. Each tier adds one thing and loses another. Moving up does not produce a better model of everything; it produces a model of more variables and fewer controls. A mouse is not a better cell than a hepatocyte; it is a different experiment.
What each tier is actually good for
| Claim | Minimum tier | Reason |
|---|---|---|
| This enzyme controls this flux | Line or primary | Mechanism is cell-autonomous |
| This compound reduces lipid accumulation | Line, confirmed in primary | Convenience plus fidelity |
| This gene causes this metabolic phenotype | iPSC or mouse | Requires genetic control in a physiological context |
| This pathway drives fibrosis | Co-culture or organoid | Requires matrix-depositing cells |
| This state promotes tumour growth | Mouse | Requires a host |
| This metabolite predicts outcome | Cohort | Requires the disease population |
Caveat on iPSC. iPSC-derived cells are fetal-like in metabolism: hepatocytes have low CYP and immature mitochondrial function, cardiomyocytes are glycolytic, neurons are immature. A disease phenotype that depends on adult metabolic programmes may not appear, and its absence is not evidence of absence.
The mouse, specifically
| Requirement | Why | Commonly missing |
|---|---|---|
| Diet composition in full | Fat source and sucrose content change phenotype | % kcal from fat only |
| Housing temperature | 22 °C is below thermoneutrality; chronic cold stress | Not reported |
| Body composition | Fat and lean mass diverge | Body weight only |
| Pair-feeding | Separates composition from intake | Absent in diet studies |
| Sex and littermates | Sexually dimorphic; microbiota confound | Single sex, non-littermates |
| Time of sampling | Glucose tolerance varies across the light cycle | Single morning point |
| Genetic background | Strain differences in metabolic phenotype | Mixed background |
The second row is the one that most surprises: mice housed at standard temperature are cold, which raises energy expenditure and alters adipose and immune phenotypes — in the tissue most often being studied. A metabolic phenotyping paper that does not report housing temperature has an uncontrolled variable acting on the primary outcome.
The human cohort, specifically
| Design | Supports | Fails when |
|---|---|---|
| Cross-sectional | Association | Any causal claim |
| Prospective | Temporal order | Reverse causation still possible |
| Mendelian randomisation | Causal inference under assumptions | Pleiotropy, weak instruments |
| Intervention | Short-term causal effect | Long-term outcome, adherence |
Important distinction. A cohort measures the disease, not the mechanism. It supplies the effect size and the population, which is exactly what a model needs in order to be relevant — and exactly what most models are never calibrated against.
Decision sequence
- Write the claim as a single sentence with a tissue and a timescale.
- Identify the smallest tier that contains every element the sentence requires.
- Run the mechanism there.
- Confirm in one tier up, with the specific element that tier adds.
- Report which elements each tier supplied and which it did not.
Step 5 is what most papers omit, and it is what allows a reader to know how far the claim travels.
Failures that recur
- • Convenience-first model choice, then a claim written to fit it.
- • Immortalised line used for identity-dependent biology. HepG2 for hepatocyte function, 3T3-L1 for human adipose.
- • iPSC-derived cells assumed mature. They are fetal-like.
- • Mouse study without housing temperature or diet composition.
- • Fibrosis claimed without matrix-depositing cells.
- • Spheroid called a microenvironment. It is a gradient.
- • Cohort association described as mechanism.
- • No confirmation tier. A single-tier claim presented as general.
Where this connects
- • Disease pillar supplies the tissue-and-timescale frame and the model requirements list this article operationalises.
- • Glucose, lipid, amino acid and mitochondrial pillars supply the readouts appropriate to each tissue.
- • MASH cell models, adipocyte models and spheroid articles supply the specific constraints of the three most commonly used systems.
Scientific interpretation and experimental design
- • Answer the four questions first. Tissue, timescale, systemic component, architecture.
- • Choose the smallest tier that contains every required element.
- • Add one tier for confirmation, and name what it adds.
- • Report the elements each tier lacked. That defines the claim's reach.
- • Check iPSC maturity before interpreting a negative result.
- • Report housing temperature and full diet composition.
- • Calibrate models against cohort effect sizes where they exist.
Selected references for further reading
- • Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine. 2018;24:908–922.
- • Febbraio MA, et al. Preclinical models for studying NASH-driven HCC: how useful are they? Cell Metabolism. 2019;29:18–26.
- • Maloney SK, Fuller A, Mitchell D, Gordon C, Overton JM. Translating animal model research: does it matter that our rodents are cold? Physiology. 2014;29:413–420.
- • Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nature Reviews Genetics. 2019;20:377–388.
- • Hirschhaeuser F, et al. Multicellular tumor spheroids: an underestimated tool is catching up again. Journal of Biotechnology. 2010;148:3–15.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »